NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)

Interventions: Drug: tipifarnib

First Posted Date: 2004-10-08

Last Posted Date: 2013-01-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 296

Registration Number: NCT00093418

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Stage IIIB Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer

Interventions: Radiation: 3-dimensional conformal radiation therapy
Drug: bortezomib
Drug: paclitaxel
Drug: carboplatin

First Posted Date: 2004-10-08

Last Posted Date: 2017-12-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 52

Registration Number: NCT00093756

Locations: 🇺🇸
Mcdonough District Hospital, Macomb, Illinois, United States
🇺🇸
Carle Foundation - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸
Siouxland Regional Cancer Center, Sioux City, Iowa, United States

and more 139 locations

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

Phase 1

Completed

Conditions: Adult Anaplastic Astrocytoma
Adult Anaplastic Oligodendroglioma
Adult Giant Cell Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Tumor

Interventions: Drug: sorafenib tosylate
Other: pharmacological study

First Posted Date: 2004-10-08

Last Posted Date: 2014-05-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT00093613

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States

and more 7 locations

Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer

Phase 2

Completed

Conditions: Primary Peritoneal Cavity Cancer
Stage IV Ovarian Epithelial Cancer
Recurrent Ovarian Epithelial Cancer
Stage III Ovarian Epithelial Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: tanespimycin

First Posted Date: 2004-10-08

Last Posted Date: 2014-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT00093496

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

Phase 2

Completed

Conditions: Metastatic Gastrointestinal Carcinoid Tumor
Pulmonary Carcinoid Tumor
Recurrent Gastrointestinal Carcinoid Tumor
Recurrent Islet Cell Carcinoma

Interventions: Drug: temsirolimus
Other: laboratory biomarker analysis

First Posted Date: 2004-10-08

Last Posted Date: 2017-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00093782

Locations: 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada

Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

Phase 2

Completed

Conditions: Primary Peritoneal Carcinoma
Recurrent Ovarian Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Sorafenib Tosylate

First Posted Date: 2004-10-08

Last Posted Date: 2019-07-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 73

Registration Number: NCT00093626

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Exercise in Women at Risk for Breast Cancer

Phase 2

Completed

Conditions: Breast Neoplasms

First Posted Date: 2004-09-27

Last Posted Date: 2017-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 88

Registration Number: NCT00092950

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Program to Reduce Incontinence by Diet and Exercise

Not Applicable

Completed

Conditions: Urinary Incontinence

Interventions: Behavioral: Lifestyle & Behavioral Change Program
Behavioral: Structured Education Program

First Posted Date: 2004-09-22

Last Posted Date: 2020-04-16

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 338

Registration Number: NCT00091988

Locations: 🇺🇸
University of Arkansas, Little Rock, Arkansas, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
Miriam Hospital/Brown University, Providence, Rhode Island, United States

and more 1 locations

Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease

Recruiting

Conditions: Chronic Graft vs. Host Disease

First Posted Date: 2004-09-22

Last Posted Date: 2025-06-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 650

Registration Number: NCT00092235

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Phase 2

Active, not recruiting

Conditions: Lymphoproliferative Disorder
HIV
HHV-8
Malignancy

Interventions: Drug: Etoposide
Drug: Interferon-alpha
Other: Observation Only
Drug: Sirolimus
Drug: Zidovudine
Drug: Rituximab
Drug: Bortezomib
Drug: Doxorubicin
Drug: Liposomal Doxorubicin
Drug: Valganciclovir
Drug: Vincristine
Drug: Cyclophosphamide
Drug: Filgrastim (G-CSF)
Drug: Prednisone

First Posted Date: 2004-09-22

Last Posted Date: 2025-06-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 75

Registration Number: NCT00092222

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

AI-Powered Research

Premium Access

NATIONAL INSTITUTES OF HEALTH

S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia

Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

Exercise in Women at Risk for Breast Cancer

Program to Reduce Incontinence by Diet and Exercise

Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity